2011 16th Taiwan Joint Cancer Conference, Taipei, Taiwan.

Hsu FT, Chiang IT, Kuo YC, Hwang JJ: Sorafenib inhibits radiation-induced radioresistance via suppression of NF-kB and its regulated down-stream gene products in human hepatocellular carcinoma.

 

2011 World Molecular Imaging Congress, San Diego, USA.

Hsu FT, Chiang IT, Kuo YC, Hwang JJ: Sorafenib inhibits radiation-induced radioresistance via suppression of NF-kB and its regulated down-stream gene products in human hepatocellular carcinoma.

 

2011 International Symposium on Frontier Biomedical & Molecular Imaging

Hsu FT, Chiang IT, Kuo YC, Hwang JJ: Sorafenib inhibits radiation-induced radioresistance via suppression of NF-kB and its regulated down-stream gene products in human hepatocellular carcinoma.

 

2012 17th Taiwan Joint Cancer Conference, Taipei, Taiwan.

Hsu FT, Chiang IT, Liu YC, Wang HE, Liu RS, Hwang JJ: Using NF-kB molecular imaging to evaluate the therapeutic effect of sorafenib in hepatocellular carcinoma.

 

2012 World Molecular Imaging Congress, Dublin, Ireland

Hsu FT, Chiang IT, Liu YC, Wang HE, Liu RS, Hwang JJ: Using NF-kB molecular imaging to evaluate the therapeutic effect of sorafenib in hepatocellular carcinoma.

 

2013 World Molecular Imaging Congress, Savannah, USA

1. Hsu FT, Chen TC, Chiang IT, Hwang JJ: Immunomodulation of low-dose doxorubicin on adoptive therapy with T cell functional imaging in mice.

2. Chen YC, Hsu FT, Chiang IT, Hwang JJ: Sorafenib Enhances therapeutic efficacy of vorinostat via inhibition of ERK/NF-kB pathway in human HCC.

3. Betty Chang, Hsu FT, Chiang IT, Hwang JJ: Combination effects of sorafenib with ionizing radiation on human OSCC.

 

2014 19th Taiwan Joint Cancer Conference, Taipei, Taiwan.

Hsu FT, Chiang IT, Hwang JJ: Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through inhibition of vorinostat-induced ERK/NF-kB signaling transduction.

 

2014 9th Symposium on Medical Imaging and Radiological Sciences Congress, Taipei, Taiwan

Hsu FT, Chiang IT, Hwang JJ: Optimal time schedule and possible mechanism of sorafenib combined with radiotherapy in Human Hepatocellular Carcinoma.

 

2014 International Symposium on Cancer Research: From Basic Sciences to Clinics, Taipei, Taiwan

Tsai PH, Hsu FT, Liu HS, Lu CF, Hsieh LC, Chen CY. Advanced MR imaging and radiogenomics in gliomas:  design and method.

 

2015 Radiological Society of the Republic of China, Taipei, Taiwan

Hsu FT, Lu CF, Lu CF, Lu CF, Lu CF, Hsieh LC, Chen CY: Radiogenomics of Malignant Gliomas by linking Physiological MR Imaging, and Genetic alternations.

 

2016 International Society for Magnetic Resonance in Medicine, Singapore

1. Chen CY, Hsu FT, Liu HS, Tsai PH, Tsai PH, Kao YC, Hsieh LC, and Liao PY: Low Apparent Diffusion Coefficient Values Correlate with Enhancing Mitosis and Cell Proliferation Expression in glioblastoma using Locus-Specific Radiogenomic Map.

2. Tsai PH, Chen YC, Chiang SW, Liu HS, Hsu FT, Kao YC, et al: Increased Anisotropy as Possible Compensatory Plasticity of Ventral Thalamic Nuclei to Motor Impairment In Patients with Idiopathic Normal Pressure Hydrocephalus.

 

2017 Radiological Society of North America, Chicago, USA

1. Hsu FT, Liu HS, Ali AA, Chen CY: Estimating Targeting and Therapeutic Efficacy of Erlotinib Conjugated Iron Oxide Nanoparticles in Lung Cancer by Quantitative MRI and NF-kB Reporter Gene System.

2. Chen CY, Lu CF, Hsu FT, Blakeley P, Hsieh LC, Kao YJ, et al: Personalized Survival Prediction Using Random Forest Survival Model on MR Radiomic Features in Gliomas.

 

2018 Asian-Oceanian Congress of Neuroradiology, Taipei, Taiwan

Hsu FT, Lu CF, Chen CY: Low Apparent Diffusion Coefficient Values Correlate with Enhancing Mitosis and Cell Proliferation Expression in Glioblastoma by Radiogenomic Map.

 

2018 World Molecular Imaging Congress, Seattle, USA

1. Chang Y and Hsu FT: Calculaon of Praccal Bone Density Value by Gemstone Spectral Abdomen CT Imaging in Asian Population.

2. Chiang IT, Liu YC, Hsu FT: Evaluate Therapeutic Efficacy and Molecular Mechanism of Regorafenib Combined with Temozolomide in Glioblastoma by Multimodality Molecular Imaging In Vivo.

 

2019 Taiwan Joint Cancer Conference - TJCC 24th

Yueh PF, Hsu FT: Imipramine Induces Apoptosis, DNA damage and Inhibits Invasion via suppression of NF-kB Activation in Non-small cells lung cancer

 

2019 Joint Conferences on Biotechnology of China Medical University and Asia University

Tan ZL, Lin SS, Hsu FT: Hyperforin inhibits NF-κB-mediated metastatic potential in human bladder cancer cells

​

2020 American Association for Cancer Research, USA

Yueh PF, Hsu FT: Imipramine induced apoptosis and inhibits invasion via suppression of EGFR/ERK/NF-kappaB activation in non-small cells lung cancer.

​

2020 Joint Conference on Biotechnology China Medical University and Asia University, Taiwan

1. Tan ZL, Lin SS, Hsu FT: Therapeutic Efficacy and Mechanism Investigation of Quetiapine in Hepatocellular carcinoma.

2. Wang CL, Hsu FT: Investigate the therapeutic efficacy of Palbociclib combined with PD-L1 inhibitor on OSCC.

3. Yueh PF, Hsu FT: Imipramine Induces Apoptosis and Inhibits Invasion via Suppression of EGFR/PKCδ/ERK/NF-κB Activation in Non-Small Cells Lung Cancer

4. Chao TL, Hsu FT: Lenvatinib Induces Apoptosis, Inhibits Invasion and Migration via Suppression of  NF-kB Activation in Hepatocellular Carcinoma

5. Lee SR, Hsu FT: Identify the treatment efficacy of magnolol on bladder cancer.

6. Ku HJ, Hsu FT: Mechanism and effectiveness of amentoflavone treatment on colorectal cancer

​

2021 Joint Conference on Biotechnology China Medical University and Asia University, Taiwan

1. Wang CL, Hsu FT: Combination of palbociclib with anti-PD-L1 was associated with CXCR4 inactivation and enhance efficacy in oral squamous cell carcinoma therapies.

2. Tan P, Hsu FT: Tumor inhibition role of fluoxetine combine radiation via RANK/RANKL signaling pathway. 

3. Tan ZL, Hsu FT: Amentoflavone reverse cisplatin induced NF-κB activation and enhance therapeutic efficacy in Oral squamous cell carcinoma.

4. Dong DC, Liu YC, Hsu FT: Investigate immune regulation and PI3K/AKT inactivation of tyrosine kinase inhibitor combined with PD-L1 inhibitor in glioblastoma.

5. Huang BH, Hsu FT: Induction of Apoptosis Through Extrinsic/Intrinsic Pathways and Suppression of NF-κB Activation are Associated with Lenvatinib‐inhibited Tumor Growth in Non-small Cell Lung Cancer

6. Pai KJ, Hsu FT: The efficacy and mechanism of combining regorafenib and PD-L1 Inhibitor in bladder cancer.

​

2021 AACR Virtual Annual Meeting 

1. Ku HJ, Tan ZL, Chang Y, Chiang IT, Chiang CH, Hsu FT: Amentoflavone inhibits cell proliferation and metastasis in colorectal cancer was associated with inactivation of Gli1.

2. Chao TL, Tan ZL, Chiang IT, Chang Y, Hsu FT:Lenvatinib induces apoptosis and inhibits metastasis through downregulate Wnt/GSK3β/NF-κB in Hepatocellular carcinoma.

3. Lee SR, Tan ZL, Chang Y, Chiang IT, Chiang CH, Hsu FT:Magnolol induces apoptosis and inhibits metastasis via suppression of NF-κB activation in human bladder cancer.

4. Wang CL, Tan ZL, Chang Y, Chiang IT, Chiang CH, Hsu FT:Palbociclib enhances anti-PD-L1 therapeutic efficacy in oral squamous cell carcinoma was associated with CXCR4 inactivation.

​

2022 Joint Conference on Biotechnology China Medical University and Asia University, Taiwan

1. Tan ZL, Hsu FT: Anti-depressants fluoxetine induces apoptosis and inhibits tumor progression on muscle invasive bladder cancer.

2. Ku HJ, Hsu FT: Amentoflavone inhibits metastasis and cancer stemness in colorectal cancer was associated with inactivation of GLI-1.

3. Lee SR, Hsu FT:Induction of miR-124 via magnolol was associated with NF-kB inactivation and enhanced therapeutic efficacy in bladder cancer.

4. Dong DC, Hsu FT:Investigate Immune Regulation and GSK3β/β-catenin Inactivation via Regorafenib Combined with PD-L1 Inhibitor in Glioblastoma.

5. Pai KJ, Hsu FT:Regorafenib enhanced anti-bladder cancer efficacy of anti-PD-L1

6. Lo TL, Hsu FT:Investigate mechanism of imipramine efficacy on bladder cancer treatment

​

2022 AACR Virtual Annual Meeting 

1. Pai KJ, Hsu FT: Investigate the Mechanism and Treatment Efficacy of Regorafenib Combined with Anti-PD-L1 on Bladder Cancer.

2. Tan P, Hsu FT:Fluoxetine inhibit osteosarcoma progression via RANK/RANKL signaling pathway

3. Lee SR, Tan ZL, Chang Y, Chiang IT, Chiang CH, Hsu FT:Magnolol induces apoptosis and inhibits invasion ability via suppression of STAT3 signaling in glioblastoma multiforme cells.

​

2023 AACR Annual Meeting

   1. Yueh PW, Hsu FT:The potential of 18β-glycyrrhetinic acid benefit lenvatinib induced cytotoxicity on hepatocellular carcinoma.
   2. Chen YT, Hsu FT: Hyperforin induces apoptosis and inhibits invasion via inhibiting AKT/NF-KB signaling pathway in colorectal

       cancer cells.

   3. Liao TL, Hsu FT: Application of AZD2281 combine with radiation therapy in glioblastoma.

   4. Yueh PF, Hsu FT:Evaluation of liposome encapsulated sunitinib efficacy and immune modulation on renal cell carcinoma.
   5. Peggy T, Hsu FT: Fluoxetine mediate radiosensitivity and inhibit metastasis of Osteosarcoma cells via RANK/RANKL Signaling.
   6. Pai KJ, Hsu FT:Regorafenib enhance PD-L1 expression via ATM activation and evaluate the therapeutic efficacy of combining PD-

       L1 antibody on bladder cancer.
   7. Dong DC, Hsu FT: Investigate Immune Regulation and Therapeutic Efficacy via Regorafenib Combined with PD-L1 Inhibitor in     

       Glioblastoma.

​​

2024 AACR Annual Meeting

1. Chen YT, Tsai YT, Hsu FT, Tu HF: Evaluate the potential sensitization effect and underlying mechanism of lenvatinib on cisplatin resistance oral squamous cell carcinoma.

2. Liao TL, Chiang IT, Huang BH , Hsu FT, Chan MH: Enhancing Radiotherapy with Lenvatinib by Targeting the CXCL13/CXCR5/NF-ΚB Axis.

3. Tsai YT, Chen YT, Hsu FT, Tsai JJ, Liu YC: Amentoflavone enhances regorafenib-induced apoptosis and -inhibited invasion via inactivating STAT3/NF-ΚB signaling pathway in Hepatocellular carcinoma.

4. Lu RE, Chen BX, Hsu FT, Chiang IT: Evaluate the treatment efficacy of magnolol combined with cisplatin in non-small cell lung cancer.

5. Chen BX, Liao TL, Lu RE, Hsu FT, Chang Y: To investigate the effect of fluoxetine combined with radiation therapy on hepatocellular Carcinoma.

​

​

​

​

​